retatrutide diabetes type 1 Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Reta for type 1 diabetic

Over the 20th century, additional treatments were developed and FDA approved for treatment of overweight and obesity, including phentermine, phentermine/topiramate, orlistat, and naltrexone/bupropion

It has not been submitted for FDA approval yet

FAQs Retatrutide is a new medicine that is still going through tests

A key structural feature is the incorporation of an alpha-aminoisobutyric acid (Aib) at several positions to enhance proteolytic stability against dipeptidyl peptidase-4 (DPP-4)

People taking GLP-1 medications need balanced meals with protein, fiber-rich carbohydrates, and lean fats and may have even been told to follow a 1200 calorie meal plan

Mol Metab (2021) 46:101102